 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Oct 09, 2019 |
| Title |
β-Catenin mutations as determinants of hepatoblastoma phenotypes in mice |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Hepatoblastoma (HB) is the most common pediatric liver cancer. While long-term survival is generally favorable, it is dependent upon clinical stage, tumor histology and a variety of biochemical and molecular features. HB appears almost exclusively before the age of three years, is represented by seven histologic subtypes and is usually associated with highly heterogeneous somatic mutations in the CTNNB1 gene, which encodes b-catenin, a Wnt ligand-responsive transcriptional co-factor. Numerous recurrent b-catenin mutations, not previously documented in HB, have also been identified in various other pediatric and adult cancer types. Little is known regarding the underlying factors that determine the above HB features and behaviors or whether non-HB-associated b-catenin mutations are tumorigenic when expressed in hepatocytes. Here, we investigated the oncogenic properties of 14 different HB- and non-HB-associated b-catenin mutants encoded by Sleeping Beauty vectors following their delivery into the liver by hydrodynamic tail vein injection. We show that all b-catenin mutations, as well as wild-type b-catenin are tumorigenic when co-expressed with a mutant form of yes-associated protein. However, tumor growth rates, histologies, nuclear:cytoplasmic partitioning and metabolic and transcriptional landscapes were strongly influenced by the identities of the b-catenin mutations. These findings provide a context for understanding at the molecular level the notable biological diversity of this important pediatric cancer.
|
| |
|
| Overall design |
RNA purification from five representative tumors of each group was performed using Qiagen RNAeasy columns (Qiagen, Inc., Valencia, CA) followed by DNase digestion. Sample integrity was measured using an Agilent 2100 Bioanalyzer (Agilent Technologies, Foster City, CA). All samples had RIN values of 8.5-10 prior to any further processing. Samples for sequencing were prepared using an NEB NEBNext Ultra Directional RNA Library Prep kit according to the directions provided by the vendor (New England Biolab, Beverly, MA) and sequencing was performed on a NovaSeq 6000 Instrument (Illumina, Inc., San Diego, CA) by Novagene, Inc. (Sacramento, CA).
|
| |
|
| Contributor(s) |
Wang H, Prochownik EV |
| Citation(s) |
31597698, 35259493 |
| Submission date |
Apr 23, 2019 |
| Last update date |
Aug 28, 2023 |
| Contact name |
Edward V Prochownik |
| E-mail(s) |
edward.prochownik@chp.edu
|
| Phone |
412-692-6795
|
| Organization name |
Children’s Hospital of Pittsburgh of UPMC
|
| Department |
Division of Hematology/Oncology
|
| Street address |
4401 Penn Ave.
|
| City |
Pittsburgh |
| State/province |
PA |
| ZIP/Postal code |
15224 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
|
| Samples (50)
|
|
| Relations |
| BioProject |
PRJNA534224 |
| SRA |
SRP193449 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE130178_Expression_Browser_-CLC.xlsx |
89.9 Mb |
(ftp)(http) |
XLSX |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data are available on Series record |
|
|
|
|
 |
Less...
More...